Merck & Co. Inc. (MRK)
83.56
0.55 (0.66%)
At close: Feb 18, 2025, 3:59 PM
83.29
-0.33%
After-hours: Feb 18, 2025, 07:47 PM EST
undefined% (undefined)
| Bid | 83.07 |
| Market Cap | 211.39B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 6.74 |
| PE Ratio (ttm) | 12.4 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 83.35 |
| Volume | 17,266,403 |
| Avg. Volume (20D) | 13,664,833 |
| Open | 81.13 |
| Previous Close | 83.01 |
| Day's Range | 81.11 - 83.58 |
| 52-Week Range | 81.11 - 134.63 |
| Beta | undefined |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Jan 13, 1978
Employees 70,000
Stock Exchange NYSE
Ticker Symbol MRK
Website https://www.merck.com
Analyst Forecast
According to 15 analyst ratings, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $110, which is an increase of 31.63% from the latest price.
Buy 53.33%
Hold 33.33%
Sell 6.67%
Next Earnings Release
Merck & Co. Inc. is scheduled to release its earnings on Apr 24, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
-9.07%
Merck shares are trading lower after the company i...
Unlock content with
Pro Subscription
3 weeks ago
+2.5%
Merck shares are trading higher after the company announced WELIREG has gained FDA priority review.
